Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01036568 · ClinicalTrials.gov registry record

Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
121
Enrollment target

NCT01036568: Completed study, sponsored by National Institute on Drug Abuse (NIDA).

NCT01036568 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 121 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01036568 has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
121 participants
Enrollment target

Study Summary

Background: \- Eye tracking, the ability to focus on and follow a moving target with the eyes, is often difficult for people who have schizophrenia. Research has shown that first-degree relatives of people with schizophrenia, such as parents and siblings, also tend to have difficulty with smooth eye movement and eye tracking. Researchers are interested in using functional magnetic resonance imaging (fMRI) to study brain activity during eye tracking tests in order to better understand the effect that schizophrenia has on brain function. Objectives: \- To study eye-tracking and eye-tracking impairments in people with and without schizophrenia. Eligibility: \- Individuals between 18 and 62 years of age in one of three groups: (1) patients who have been diagnosed with schizophrenia/schizoaffective disorder, (2) first-degree relatives of patients in group 1, and (3) healthy volunteers with no family history of psychosis. Design: * The study will involve two visits, one screening session and one testing session. Each session will take about 3 hours. * Participants will be asked to avoid consuming alcohol and restrict consumption of caffeine before the start of the study. Participants will provide urine and breath samples to be tested for chemicals that may interfere with the study. * Participants will visit the clinical center the morning of the day before the scanning session to provide blood and urine samples as required. Participants will return and be admitted for an overnight stay later that afternoon or evening. * During the screening session, participants will provide a medical and psychological history, provide blood samples, and learn the eye movement tasks they will do during the scanning session. * During the scanning session, participants will have an fMRI scan. During the scan, they will perform eye movement tasks that involve following moving light targets on a screen, and will also perform other tasks that test the ability to think and pay attention.

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2006-02-14
Est. Completion 2013-03-07

What the finished NCT01036568 record still lists

NCT01036568 is an observational study that tracks outcomes without assigning an intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01036568 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01036568 about?

NCT01036568 is a clinical study titled "Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia". Background: \- Eye tracking, the ability to focus on and follow a moving target with the eyes, is often difficult for people who have schizophrenia. Research has shown that first-degree relatives of people with schizophrenia, such as parents and siblings, also tend to have difficulty with smooth ey...

What is the current status of trial NCT01036568?

This trial is currently completed. The enrollment target is 121 participants. The study started on 2006-02-14. Estimated completion is 2013-03-07.

Who is sponsoring clinical trial NCT01036568?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03476681 · 121 participants · Phase 1

    Study of NEO-201 in Solid Tumors Expansion Cohorts

  • NCT04655118 · 121 participants · Phase 2

    Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

  • NCT04676802 · 121 participants · Phase 2

    Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone

  • NCT05169515 · 121 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01036568, the US trial registry maintained by the National Library of Medicine. NCT01036568 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.